PetMeds® Announces Its Fourth Quarter and Fiscal Year End Financial Results
PetMed Express (NASDAQ: PETS) reported its financial results for the fourth quarter and fiscal year ending March 31, 2024. Quarterly net sales rose 6.6% to $66.5 million, driven by the PetCareRx acquisition, but offset by a decline in legacy sales. However, the company posted a net loss of $5.0 million, or $0.25 per diluted share, primarily due to increased G&A and marketing expenses. Adjusted EBITDA fell to $0.5 million from $3.6 million in the prior year.
For the full fiscal year, net sales increased 9.5% to $281.1 million. The company recorded a net loss of $7.5 million, compared to a net income of $5.1 million the previous year, again due to higher G&A and marketing expenses. Annual Adjusted EBITDA declined to $8.2 million from $19.8 million. CEO Sandra Campos noted challenges in the macro environment and industry dynamics but emphasized efforts to improve systems and processes for better customer experience. Looking ahead, the company aims to drive growth, improve profitability, and enhance customer satisfaction.
- Quarterly net sales increased by 6.6% to $66.5 million.
- Annual net sales rose by 9.5% to $281.1 million.
- Higher gross margin from PetCareRx's membership program.
- Ongoing investment in technology aimed at improving customer experience.
- Net loss of $5.0 million for Q4 2024, compared to a $0.2 million loss in Q4 2023.
- Annual net loss of $7.5 million, compared to a net income of $5.1 million in the prior year.
- Increased G&A and marketing expenses contributing to losses.
- Quarterly Adjusted EBITDA dropped to $0.5 million from $3.6 million.
- Annual Adjusted EBITDA decreased to $8.2 million from $19.8 million.
- Decline in legacy sales partially offsetting gains from PetCareRx.
Insights
PetMed Express reported net sales of
The fiscal year story is similar. Annual net sales rose
This discrepancy between revenue and profitability is a red flag. While the acquisition has bolstered top-line performance, it has yet to translate into bottom-line gains. Investors should closely monitor G&A and marketing expenses, which have ballooned and are eroding profitability.
In the short term, this could pressure the stock given the current net loss and higher operational costs. However, if management's initiatives to improve customer experience and streamline operations prove effective, we might see better profitability in the long term.
From a market perspective, PetMed Express' performance showcases a classic case of acquisition growing pains. The integration of PetCareRx brought in higher sales but also added considerable operational costs and complexity. Customer experience issues, particularly related to new system implementations, further exacerbated these challenges, impacting customer satisfaction and, ultimately, revenues.
The company's strategic priorities for FY2025 focus on growth, profitability and customer satisfaction. These are essential goals, but investors should be cautious of the execution risk involved. Market players often face setbacks when integrating new systems and restructuring operations, as seen in the slowed call center response times.
In terms of industry dynamics, the pet healthcare market is growing, driven by increased pet ownership and higher spending on pet health. This offers a favorable backdrop for PetMed Express’ long-term growth. However, the competitive landscape is intensifying, adding pressure to innovate and optimize operational efficiency.
DELRAY BEACH, Fla., June 11, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its fourth quarter and fiscal year ended March 31, 2024.
Quarterly Highlights
- Net sales for the quarter ended March 31, 2024, were
$66.5 million , compared to$62.4 million for the fourth quarter in the prior year, an increase of6.6% , driven by the acquisition of PetCareRx partially offset by a decline in PetMeds legacy sales. - Net loss for the quarter ended March 31, 2024 was
$(5.0) million , or$(0.25) diluted earnings per share. This compares to net loss of$(0.2) million , or$(0.01) diluted earnings per share, for the prior year quarter ended March 31, 2023. The increase in the net loss can be attributed to additional G&A, marketing expenses and an increase in depreciation and amortization associated with the acquisition. - Adjusted EBITDA1 was
$0.5 million for the current year quarter, compared to Adjusted EBITDA of$3.6 million , for the quarter ended March 31, 2023.
Annual Highlights
- Net sales for the fiscal year ended March 31, 2024, were
$281.1 million , compared to$256.6 million for the prior year, an increase of9.5% , driven by the acquisition of PetCareRx partially offset by a decline in PetMeds legacy sales. - Net loss for the fiscal year ended March 31, 2024 was
$(7.5) million , or$(0.37) diluted earnings per share. This compares to net income of$5.1 million , or$0.25 diluted earnings per share, for the prior fiscal year ended March 31, 2023. The net loss can be attributed to additional G&A, marketing expenses and an increase in depreciation and amortization. These increases were offset by higher gross margin associated with PetCareRx as driven by their membership program fee, partially offset by a decline in PetMeds’ legacy gross margin. - Adjusted EBITDA was
$8.2 million , for the fiscal year ended March 31, 2024, compared to Adjusted EBITDA of$19.8 million for the fiscal year ended March 31, 2023.
“Our results were negatively impacted by a challenging macro environment and industry dynamics, as well as a slow down in call center response times due to the implementation of our new Order Management System and Autoship platforms during the fourth quarter,” said Sandra Campos, CEO & President. “We are moving swiftly to continue to improve our systems and processes to drive a better customer experience, along with investing in additional technology resources.”
“PetMeds and PetCareRx have been synonymous with delivering top-quality pet healthcare products for over two decades, addressing preventive care, chronic and acute medical needs for dogs, cats, and horses. Each year, millions of customers trust our integrated ecosystem of pet health and wellness products and services for the care of their beloved pets.”
Ms. Campos concluded, “Looking ahead to FY2025, our strategic priorities are focused on driving growth, improving profitability, and increasing our key customer satisfaction metrics. Consolidating business operations will simplify our structure, reduce cost and strengthen alignment across the organization. We will also sharpen and amplify our messaging with a comprehensive marketing plan and look to create efficiencies by leveraging investments in modern customized technology frameworks.”
This afternoon the Company will host a conference call to review the quarter’s financial results.
Time: 4:30 P.M. Eastern Time, June 11, 2024
Public call dial in (877) 407-0789 (toll free) or (201) 689-8562.
Webcast stream link: https://investors.petmeds.com for those who wish to stream the call via webcast.
Replay: Available until June 25, 2024, at 11:59 P.M Eastern Time.
To access the replay, call (844) 512-2921 (toll free) or (412) 317-6671 and enter passcode 13746751.
About PetMed Express, Inc.
Founded in 1996, PetMeds is a leader in pioneering the digital pet pharmacy industry. As a national online retailer, PetMeds.com and PetCareRx.com are top choices for delivering preventive and chronic symptom prescriptions and OTC medications and products through their thousands of veterinary partners and a loyal customer base. Leveraging telehealth and insurance partnerships, they offer value and convenience to pet families at every stage of their pets' lives, whether dogs, cats, or horses. PetMeds and PetCareRx provide a comprehensive range of medications, food products, and essential supplies through their websites, www.PetMeds.com and www.PetCareRx.com.
Forward Looking Statement
This press release may contain “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties, including the Company’s ability to meet the objectives included in its business plan. Important factors that could cause results to differ materially from those indicated by such forward-looking statements are set forth in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in the Company’s Annual Report on Form 10-K/A for the year ended March 31, 2023. The Company’s future results may also be impacted by other risk factors listed from time to time in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the Company's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.
Investor Contact:
ICR, LLC
John Mills
(646) 277-1254
Reed Anderson
(646) 277-1260
investor@petmeds.com
| PETMED EXPRESS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except for share and per share amounts) (Unaudited) | |||||||
| March 31, 2024 | March 31, 2023 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 55,296 | $ | 104,086 | |||
| Accounts receivable, less allowance for credit losses of | 3,283 | 1,740 | |||||
| Inventories | 28,556 | 19,023 | |||||
| Prepaid expenses and other current assets | 6,325 | 4,719 | |||||
| Prepaid income taxes | 188 | 863 | |||||
| Total current assets | 93,648 | 130,431 | |||||
| Noncurrent assets: | |||||||
| Property and equipment, net | 26,657 | 26,178 | |||||
| Intangible and other assets, net | 16,503 | 5,860 | |||||
| Goodwill | 26,658 | — | |||||
| Operating lease right-of-use assets, net | 1,432 | — | |||||
| Deferred tax assets, net | 4,986 | 5,009 | |||||
| Total noncurrent assets | 76,236 | 37,047 | |||||
| Total assets | $ | 169,884 | $ | 167,478 | |||
| LIABILITIES AND SHAREHOLDERS' EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 37,024 | $ | 25,208 | |||
| Sales tax payable | 25,012 | 26,113 | |||||
| Accrued expenses and other current liabilities | 7,060 | 6,191 | |||||
| Current operating lease liabilities | 459 | — | |||||
| Deferred revenue | 2,603 | — | |||||
| Total current liabilities | 72,158 | 57,512 | |||||
| Long-term operating lease liabilities | 995 | — | |||||
| Total liabilities | 73,153 | 57,512 | |||||
| Shareholders' equity: | |||||||
| Preferred stock, $.001 par value, 5,000,000 shares authorized; 2,500 convertible shares issued and outstanding with a liquidation preference of | 9 | 9 | |||||
| Common stock, $.001 par value, 40,000,000 shares authorized; 21,148,692 and 21,084,302 shares issued and outstanding, respectively | 21 | 21 | |||||
| Additional paid-in capital | 25,146 | 18,277 | |||||
| Retained earnings | 71,555 | 91,659 | |||||
| Total shareholders' equity | 96,731 | 109,966 | |||||
| Total liabilities and shareholders' equity | $ | 169,884 | $ | 167,478 | |||
| PETMED EXPRESS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF (LOSS) INCOME (In thousands, except for share and per share amounts) (Unaudited) | |||||||||||||||
| Three Months Ended March 31, | Year Ended March 31, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Net sales | $ | 66,504 | $ | 62,407 | $ | 281,064 | $ | 256,579 | |||||||
| Cost of sales | 48,327 | 45,025 | 202,416 | 185,844 | |||||||||||
| Gross profit | 18,177 | 17,382 | 78,648 | 70,735 | |||||||||||
| Operating expenses: | |||||||||||||||
| General and administrative | 14,148 | 12,045 | 55,246 | 41,714 | |||||||||||
| Advertising | 5,969 | 4,555 | 24,508 | 19,424 | |||||||||||
| Depreciation and amortization | 1,895 | 994 | 7,056 | 3,546 | |||||||||||
| Total operating expenses | 22,012 | 17,594 | 86,810 | 64,684 | |||||||||||
| (Loss) income from operations | (3,835 | ) | (212 | ) | (8,162 | ) | 6,051 | ||||||||
| Other income: | |||||||||||||||
| Interest income (expense), net | 30 | 439 | 511 | 450 | |||||||||||
| Other, net | 325 | 226 | 1,378 | 944 | |||||||||||
| Total other income (expense) | 355 | 665 | 1,889 | 1,394 | |||||||||||
| (Loss) income before provision for income taxes | (3,480 | ) | 453 | (6,273 | ) | 7,445 | |||||||||
| Provision for income taxes | 1,536 | 669 | 1,191 | 2,305 | |||||||||||
| Net (loss) income | $ | (5,016 | ) | $ | (216 | ) | $ | (7,464 | ) | $ | 5,140 | ||||
| Net (loss) income per common share: | |||||||||||||||
| Basic | $ | (0.25 | ) | $ | (0.01 | ) | $ | (0.37 | ) | $ | 0.25 | ||||
| Diluted | $ | (0.25 | ) | $ | (0.01 | ) | $ | (0.37 | ) | $ | 0.25 | ||||
| Weighted average number of common shares outstanding: | |||||||||||||||
| Basic | 20,443,052 | 20,328,688 | 20,395,959 | 20,274,786 | |||||||||||
| Diluted | 20,443,052 | 20,328,688 | 20,395,959 | 20,339,002 | |||||||||||
| Cash dividends declared per common share | $ | — | $ | 0.30 | $ | 0.60 | $ | 1.20 | |||||||
| PETMED EXPRESS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) | |||||||
| Year Ended March 31, | |||||||
| 2024 | 2023 | ||||||
| Cash flows from operating activities: | |||||||
| Net (loss) income | $ | (7,464 | ) | $ | 5,140 | ||
| Adjustments to reconcile net (loss) income to net cash provided by operating activities: | |||||||
| Depreciation and amortization | 7,056 | 3,546 | |||||
| Share based compensation | 6,869 | 6,617 | |||||
| Deferred income taxes | 292 | (1,630 | ) | ||||
| Bad debt expense | 324 | 214 | |||||
| (Increase) decrease in operating assets and increase (decrease) in liabilities: | |||||||
| Accounts receivable | (1,742 | ) | (41 | ) | |||
| Inventories | (6,417 | ) | 13,432 | ||||
| Prepaid income taxes | 675 | (182 | ) | ||||
| Prepaid expenses and other current assets | (185 | ) | 147 | ||||
| Operating lease right-of-use assets, net | 788 | — | |||||
| Accounts payable | 6,102 | (2,292 | ) | ||||
| Sales tax payable | (1,101 | ) | 1,956 | ||||
| Accrued expenses and other current liabilities | 276 | 896 | |||||
| Operating lease liabilities | (766 | ) | — | ||||
| Deferred revenue | (390 | ) | — | ||||
| Net cash provided by operating activities | 4,318 | 27,803 | |||||
| Cash flows from investing activities: | |||||||
| Purchase of minority interest investment in Vetster | (300 | ) | (5,000 | ) | |||
| Acquisition of PetCareRx, net of cash acquired | (35,859 | ) | — | ||||
| Purchases of property and equipment | (4,511 | ) | (5,260 | ) | |||
| Net cash used in investing activities | (40,670 | ) | (10,260 | ) | |||
| Cash flows from financing activities: | |||||||
| Dividends paid | (12,437 | ) | (24,537 | ) | |||
| Net cash used in financing activities | (12,437 | ) | (24,537 | ) | |||
| Net decrease in cash and cash equivalents | (48,789 | ) | (6,994 | ) | |||
| Cash and cash equivalents, at beginning of fiscal year | 104,086 | 111,080 | |||||
| Cash and cash equivalents, at end of fiscal year | $ | 55,296 | $ | 104,086 | |||
| Supplemental disclosure of cash flow information: | |||||||
| Cash paid for income taxes | $ | 130 | $ | 4,312 | |||
| Dividends payable in accrued expenses | $ | 1,466 | $ | 1,262 | |||
Non-GAAP Financial Measures
To provide investors and the market with additional information regarding our financial results, we have disclosed (see below) adjusted EBITDA, a non-GAAP financial measure that we calculate as net income excluding share-based compensation expense; depreciation and amortization; income tax provision; interest income (expense); and other non-operational expenses. We have provided reconciliations below of adjusted EBITDA to net income, the most directly comparable GAAP financial measures.
We have included adjusted EBITDA, herein, because it is a key measure used by our management and Board of Directors to evaluate our operating performance, generate future operating plans, and make strategic decisions regarding the allocation of capital. In particular, the exclusion of certain expenses in calculating adjusted EBITDA facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and other expenses. Accordingly, we believe that adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and Board of Directors.
We believe it is useful to exclude non-cash charges, such as share-based compensation expense, depreciation and amortization from our adjusted EBITDA because the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations. We believe it is useful to exclude income tax provision and interest income (expense), as neither are components of our core business operations. We also believe that it is useful to exclude other expenses, including the investment banking fee related to the Vetster partnership, acquisition costs related to PetCareRx, employee severance and an estimated state sales tax accrual as these items are not indicative of our ongoing operations. Adjusted EBITDA has limitations as a financial measure, and these non-GAAP measures should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:
- Although depreciation and amortization are non-cash charges, the assets being depreciated may have to be replaced in the future and adjusted EBITDA does not reflect capital expenditure requirements for such replacements or for new capital expenditures;
- Adjusted EBITDA does not reflect share-based compensation. Share-based compensation has been, and will continue to be for the foreseeable future, a material recurring expense in our business and an important part of our compensation strategy;
- Adjusted EBITDA does not reflect interest income (expense), net; or changes in, or cash requirements for, our working capital;
- Adjusted EBITDA does not reflect transaction related costs and other items which are either not representative of our underlying operations or are incremental costs that result from an actual or planned transaction and include litigation matters, integration consulting fees, internal salaries and wages (to the extent the individuals are assigned full-time to integration and transformation activities) and certain costs related to integrating and converging IT systems;
- Adjusted EBITDA does not reflect certain non-operating expenses including the employee severance which reduces cash available to us;
- Adjusted EBITDA does not reflect non operating expenses (income) including sales tax expense (income) relating to recording a liability for sales tax we did not collect from our customers or recognizing a gain on settlement from settling a state liability for less than recorded.
- Other companies, including companies in our industry, may calculate adjusted EBITDA differently, which reduces the measures usefulness as comparative measures.
Because of these and other limitations, Adjusted EBITDA should only be considered as supplemental to, and alongside with other GAAP based financial performance measures, including various cash flow metrics, net income, net margin, and our other GAAP results. The following table presents a reconciliation of net income, the most directly comparable GAAP measure to Adjusted EBITDA for each of the periods indicated:
| Reconciliation of Unaudited Non-GAAP Measures PetMed Express, Inc. | ||||||||||||||
| Three Months Ended | ||||||||||||||
| ($ in thousands, except percentages) | March 31, 2024 | March 31, 2023 | $ Change | % Change | ||||||||||
| Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA: | ||||||||||||||
| Net loss | $ | (5,016 | ) | $ | (216 | ) | $ | (4,800 | ) | 2222 | % | |||
| Add (subtract): | ||||||||||||||
| Share-based Compensation | $ | 1,674 | $ | 1,630 | $ | 44 | 3 | % | ||||||
| Income Taxes | $ | 1,536 | $ | 669 | $ | 867 | 130 | % | ||||||
| Depreciation and amortization | $ | 1,895 | $ | 994 | $ | 901 | 91 | % | ||||||
| Interest Income | $ | (30 | ) | $ | (439 | ) | $ | 409 | (93 | )% | ||||
| Acquisition/Partnership Transactions and Other Items | $ | 385 | $ | 1,010 | $ | (625 | ) | (62 | )% | |||||
| Employee Severance | $ | 104 | $ | — | $ | 104 | n/m | |||||||
| Adjusted EBITDA | $ | 548 | $ | 3,648 | $ | (3,100 | ) | (85 | )% | |||||
| Year Ended | ||||||||||||||
| ($ in thousands, except percentages) | March 31, 2024 | March 31, 2023 | $ Change | % Change | ||||||||||
| Consolidated Reconciliation of GAAP Net (Loss) Income to Adjusted EBITDA: | ||||||||||||||
| Net (loss) income | $ | (7,464 | ) | $ | 5,140 | $ | (12,604 | ) | (245 | )% | ||||
| Add (subtract): | ||||||||||||||
| Share-based Compensation | $ | 6,870 | $ | 6,617 | $ | 253 | 4 | % | ||||||
| Income Taxes | $ | 1,191 | $ | 2,305 | $ | (1,114 | ) | (48 | )% | |||||
| Depreciation and amortization | $ | 7,056 | $ | 3,546 | $ | 3,510 | 99 | % | ||||||
| Interest Income | $ | (511 | ) | $ | (450 | ) | $ | (61 | ) | 14 | % | |||
| Acquisition/Partnership Transactions and Other Items | $ | 1,679 | $ | 1,904 | $ | (225 | ) | (12 | )% | |||||
| Employee Severance | $ | 512 | $ | 364 | $ | 148 | 41 | % | ||||||
| Sales Tax Expense (Income) | $ | (1,088 | ) | $ | 344 | $ | (1,432 | ) | (416 | )% | ||||
| Adjusted EBITDA | $ | 8,245 | $ | 19,770 | $ | (11,525 | ) | (58 | )% | |||||
1 Adjusted EBITDA is a non-GAAP financial measure. See “Non-GAAP Financial Measures” for additional information on non-GAAP financial measures and a reconciliation to the most comparable GAAP measures.
FAQ
What were PetMeds' net sales for the fourth quarter of 2024?
What was PetMeds' net loss for the fourth quarter of 2024?
How did PetMeds' annual net sales perform in fiscal year 2024?
What was PetMeds' annual net loss for fiscal year 2024?
How did PetMeds' Adjusted EBITDA perform in the fourth quarter of 2024?
What factors contributed to PetMeds' financial losses in fiscal year 2024?
What are PetMeds' strategic priorities for fiscal year 2025?
